|
October 6, 2000
Dr. Louis R. Lamontagne, President and CEO of Neurochem Inc. interviewed by Wall
Street Reporter Magazine
Neurochem Inc. (TSX : NRM) President and CEO, Dr. Louis R. Lamontagne was interviewed on
September 29, 2000, by John Foley, Senior Analyst at the Wall Street Reporter Magazine.
The interview can be accessed by scrolling down the listing of interviews on the
www.wallstreetreporter.com/
website, in the interviews section under the letter N - for Neurochem.
Neurochem is an industry leader in the development of a novel, proprietary series of
compounds that inhibit the formation, deposit and toxic effects of amyloid fibrils on
cells within the body. Neurochem's research team has been working with international
amyloid experts on the development of therapeutic cures to amyloid-related diseases,
including Alzheimer's disease, Secondary Amyloidosis , Diabetes Type II and Hemorrhagic
Stroke (due to Cerebral Amyloid Angiopathy). Neurochem has advanced three drug candidates to
clinical trials: Alzhemed™, for the treatment of Alzheimer's disease,
Fibrillex™, for Secondary Amyloidosis, and Cerebril™, for
Hemorrhagic Stroke. At present, the Company employs over 50 people and is located in
Saint-Laurent, Canada (www.neurochem.com).
For further Information, please contact:
Dr. Lise Hébert
Vice President, Corporate Communications
lhebert@neurochem.com
275 Armand-Frappier
Laval (Quebec)
H7V 4A7
Tel: (450) 680-4500
Fax: (450) 680-4501
|
